These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 28587944)

  • 1. Short-term injection drug use changes following hepatitis C virus (HCV) assessment and treatment among persons who inject drugs with acute HCV infection.
    Artenie AA; Zang G; Daniel M; Fortier E; Jutras-Aswad D; Puzhko S; Bruneau J
    Int J Drug Policy; 2017 Sep; 47():239-243. PubMed ID: 28587944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C.
    Alavi M; Spelman T; Matthews GV; Haber PS; Day C; van Beek I; Walsh N; Yeung B; Bruneau J; Petoumenos K; Dolan K; Kaldor JM; Dore GJ; Hellard M; Grebely J;
    Int J Drug Policy; 2015 Oct; 26(10):976-83. PubMed ID: 26115881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained drug use changes after hepatitis C screening and counseling among recently infected persons who inject drugs: a longitudinal study.
    Bruneau J; Zang G; Abrahamowicz M; Jutras-Aswad D; Daniel M; Roy E
    Clin Infect Dis; 2014 Mar; 58(6):755-61. PubMed ID: 24363333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study.
    Midgard H; Hajarizadeh B; Cunningham EB; Conway B; Backmund M; Bruggmann P; Bruneau J; Bourgeois S; Dunlop A; Foster GR; Hellard M; Robaeys G; Thurnheer MC; Weltman M; Amin J; Marks PS; Quiene S; Dore GJ; Dalgard O; Grebely J;
    Int J Drug Policy; 2017 Sep; 47():230-238. PubMed ID: 28633998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Visits to primary care physicians among persons who inject drugs at high risk of hepatitis C virus infection: room for improvement.
    Artenie AA; Jutras-Aswad D; Roy É; Zang G; Bamvita JM; Lévesque A; Bruneau J
    J Viral Hepat; 2015 Oct; 22(10):792-9. PubMed ID: 25586516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimating the cascade of hepatitis C testing, care and treatment among people who inject drugs in Australia.
    Iversen J; Grebely J; Catlett B; Cunningham P; Dore GJ; Maher L
    Int J Drug Policy; 2017 Sep; 47():77-85. PubMed ID: 28578863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High hepatitis C incidence in relation to prescription opioid injection and poly-drug use: Assessing barriers to hepatitis C prevention.
    Puzhko S; Roy É; Jutras-Aswad D; Artenie AA; Fortier E; Zang G; Bruneau J
    Int J Drug Policy; 2017 Sep; 47():61-68. PubMed ID: 28666636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does informing people who inject drugs of their hepatitis C status influence their injecting behaviour? Analysis of the Networks II study.
    Aspinall EJ; Weir A; Sacks-Davis R; Spelman T; Grebely J; Higgs P; Hutchinson SJ; Hellard ME
    Int J Drug Policy; 2014 Jan; 25(1):179-82. PubMed ID: 24315504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gender differences in planning ability and hepatitis C virus among people who inject drugs.
    Scheidell JD; Khan MR; Clifford LM; Dunne EM; Keen LD; Latimer WW
    Addict Behav; 2015 Aug; 47():33-7. PubMed ID: 25863005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C Virus seroconversion among persons who inject drugs in relation to primary care physician visiting: The potential role of primary healthcare in a combined approach to Hepatitis C prevention.
    Artenie AA; Roy É; Zang G; Jutras-Aswad D; Bamvita JM; Puzhko S; Daniel M; Bruneau J
    Int J Drug Policy; 2015 Oct; 26(10):970-5. PubMed ID: 26005038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage study.
    Valerio H; Alavi M; Conway A; Silk D; Treloar C; Martinello M; Milat A; Dunlop A; Murray C; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Stevens A; Prain B; Hayllar J; Reid D; Montebello M; Wade A; Christmass M; Cock V; Dore GJ; Grebely J;
    Int J Drug Policy; 2022 Jul; 105():103706. PubMed ID: 35533635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of hepatitis C and pre-testing awareness of hepatitis C status in 1500 consecutive PWID participants at the Stockholm needle exchange program.
    Kåberg M; Hammarberg A; Lidman C; Weiland O
    Infect Dis (Lond); 2017 Oct; 49(10):728-736. PubMed ID: 28574295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C virus status awareness and test results confirmation among people who inject drugs in Ukraine.
    Iakunchykova O; Meteliuk A; Zelenev A; Mazhnaya A; Tracy M; Altice FL
    Int J Drug Policy; 2018 Jul; 57():11-17. PubMed ID: 29655101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiology of HIV and hepatitis C infection among women who inject drugs in Northeast India: a respondent-driven sampling study.
    McFall AM; Solomon SS; Lucas GM; Celentano DD; Srikrishnan AK; Kumar MS; Mehta SH
    Addiction; 2017 Aug; 112(8):1480-1487. PubMed ID: 28317210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Knowledge of hepatitis C and treatment willingness amongst people who inject drugs in an era of direct acting antivirals.
    Mah A; Hull MW; DeBeck K; Milloy MJ; Dobrer S; Nosova E; Wood E; Kerr T; Hayashi K
    Int J Drug Policy; 2017 Sep; 47():137-143. PubMed ID: 28347636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-border injection drug use and HIV and hepatitis C virus seropositivity among people who inject drugs in San Diego, California.
    Horyniak D; Wagner KD; Armenta RF; Cuevas-Mota J; Hendrickson E; Garfein RS
    Int J Drug Policy; 2017 Sep; 47():9-17. PubMed ID: 28683432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study.
    Islam N; Krajden M; Shoveller J; Gustafson P; Gilbert M; Buxton JA; Wong J; Tyndall MW; Janjua NZ;
    Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):200-210. PubMed ID: 28404135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eligibility of persons who inject drugs for treatment of hepatitis C virus infection.
    Arain A; Robaeys G
    World J Gastroenterol; 2014 Sep; 20(36):12722-33. PubMed ID: 25278674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver disease knowledge and acceptability of non-invasive liver fibrosis assessment among people who inject drugs in the drug and alcohol setting: The LiveRLife Study.
    Marshall AD; Micallef M; Erratt A; Telenta J; Treloar C; Everingham H; Jones SC; Bath N; How-Chow D; Byrne J; Harvey P; Dunlop A; Jauncey M; Read P; Collie T; Dore GJ; Grebely J
    Int J Drug Policy; 2015 Oct; 26(10):984-91. PubMed ID: 26256938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A longitudinal study of hepatitis C virus testing and infection status notification on behaviour change in people who inject drugs.
    Spelman T; Morris MD; Zang G; Rice T; Page K; Maher L; Lloyd A; Grebely J; Dore GJ; Kim AY; Shoukry NH; Hellard M; Bruneau J;
    J Epidemiol Community Health; 2015 Aug; 69(8):745-52. PubMed ID: 25814695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.